// App-Quantinova.ai

AB0674 (2021) : RAPID ADOPTION OF TELEMEDICINE IN RHEUMATOLOGY TRAINING: RESULTS FROM THE COVID-19 GLOBAL RHEUMATOLOGY ALLIANCE TRAINEE SURVEY

Researchers

Presenter

  • S. A. Yeoh

Principal Investigators

  • K. Young

  • F. Berenbaum

  • R. Conway

  • R. Grainger

  • M. Konig

  • J. Liew

  • P. M. Machado

  • S. E. Sattui

  • J. Sparks

  • P. Sufka

  • M. Ugarte-Gil

  • Z. Wallace

  • J. Yazdany

  • A. Jayatilleke

Medical Centers

  • University College London, Gastroenterology, London, United Kingdom

  • University of Texas Southwestern Medical School, Dallas, United States of America

  • Medical College of Wisconsin, Rheumatology, Milwaukee, United States of America

  • Emerson Hospital, Department of Medicine, Concord, United States of America

  • Sorbonne Université, Rheumatology, Paris, France

  • AP-HP Saint-Antoine Hospital, Rheumatology, Paris, France

  • Rheumatology, Cahors, France

  • St James Hospital, Rheumatology, Dublin, Ireland

  • University of Otago Wellington, Department of Medicine, Wellington, New Zealand

  • George Washington University, School of Medicine and Health Sciences, Washington DC, United States of America

  • The Johns Hopkins University, Baltimore, United States of America

  • Boston University, Rheumatology, Boston, United States of America

  • Hospital for Special Surgery Main Hospital, New York, United States of America

  • Harvard Medical School, Hematology, Boston, United States

  • HealthPartners & Regions Hospital, Rheumatology, St. Paul, United States of America

  • Universidad Científica del Sur, Rheumatology, Lima, Peru

  • Massachusetts General Hospital, Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Boston, United States of America

  • Temple University Lewis Katz School of Medicine, Rheumatology, Philadelphia, United States of America

Locations

  • United Kingdom

  • United States

  • France

  • Ireland

  • New Zealand

  • Peru

Companies

  • N/A

Study Components

Therapeutic Area

  • Infectious Diseases (ID)

Disease

  • Coronavirus disease

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A


Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • Pfizer

Result

  • N/A